HOWL vs. KRRO, AMRN, CRDF, TVGN, URGN, SLDB, VYGR, KOD, MNPR, and IPHA
Should you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Korro Bio (KRRO), Amarin (AMRN), Cardiff Oncology (CRDF), Tevogen Bio (TVGN), UroGen Pharma (URGN), Solid Biosciences (SLDB), Voyager Therapeutics (VYGR), Kodiak Sciences (KOD), Monopar Therapeutics (MNPR), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry.
Werewolf Therapeutics vs.
Werewolf Therapeutics (NASDAQ:HOWL) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership.
Werewolf Therapeutics has higher revenue and earnings than Korro Bio.
Werewolf Therapeutics received 8 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 69.57% of users gave Werewolf Therapeutics an outperform vote.
Werewolf Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500.
Werewolf Therapeutics presently has a consensus price target of $9.33, indicating a potential upside of 718.71%. Korro Bio has a consensus price target of $144.00, indicating a potential upside of 527.18%. Given Werewolf Therapeutics' higher probable upside, equities analysts plainly believe Werewolf Therapeutics is more favorable than Korro Bio.
64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 21.1% of Werewolf Therapeutics shares are held by insiders. Comparatively, 5.4% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Korro Bio has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Korro Bio's return on equity of -50.25% beat Werewolf Therapeutics' return on equity.
In the previous week, Werewolf Therapeutics and Werewolf Therapeutics both had 3 articles in the media. Korro Bio's average media sentiment score of 0.63 beat Werewolf Therapeutics' score of 0.24 indicating that Korro Bio is being referred to more favorably in the news media.
Summary
Korro Bio beats Werewolf Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Werewolf Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Werewolf Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:HOWL) was last updated on 3/4/2025 by MarketBeat.com Staff
Free HOWL Stock Alerts